Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Jud.Mures – page 5

136 clinical trials in Jud.Mures, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Jud.Mures at a glance
136
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

136 trials in Jud.Mures

Open in trial search

Psoriasis

Recruiting

Study on Deucravacitinib for Children with Moderate to Severe Plaque Psoriasis

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Type 2 diabetes mellitus+2

Not yet recruiting

Efficacy and Safety of Olatorepatide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Study of Daily Oral Ibutamoren Mesilate in Treatment‑Naïve Prepubertal Children with Growth Hormone Deficiency

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Ibutamoren Mesilate
  • Sponsor:Lumos Pharma LLC

Type 2 diabetes mellitus+2

Not yet recruiting

A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Study of the effects of ibutamoren mesilate in prepubertal children with growth hormone deficiency

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Ibutamoren Mesilate
  • Sponsor:Lumos Pharma LLC

Angina pectoris

Not yet recruiting

Study on the Effects of T89 and Glyceryl Trinitrate for Patients with Stable Angina

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Glyceryl Trinitrate
  • Sponsor:Tasly Pharmaceuticals Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Jud.Mures

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on Heart Failure with Reduced Ejection Fraction (HFrEF), investigating novel therapeutic approaches for patients with compromised cardiac function.

  • Treatment Evaluation
  • Safety Assessment
  • Pharmacological Studies

This research aims to enhance treatment options for patients with reduced heart pumping capacity, evaluating both effectiveness and tolerability of new therapeutic interventions over a 12-week period.

02 Therapeutic Development

Advanced clinical investigations in the field of cardiovascular medicine, specifically targeting heart failure management through controlled, randomized studies.

  • Drug Efficacy Testing
  • Patient Safety Monitoring
  • Clinical Outcomes Assessment

The research employs double-blind methodology to ensure reliable evaluation of new therapeutic compounds for heart failure treatment.

03 Clinical Assessments

Multicenter research focusing on cardiac function improvement through systematic evaluation of innovative therapeutic approaches.

  • Treatment Response Analysis
  • Pharmacokinetic Studies
  • Patient Tolerance Assessment

This research initiative aims to expand treatment options for patients with compromised cardiac function through rigorous clinical evaluation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.